CSIMarket
 
Shattuck Labs Inc   (STTK)
Other Ticker:  
 
 
Price: $8.2700 $-0.44 -5.052%
Day's High: $8.77 Week Perf: -5.27 %
Day's Low: $ 8.27 30 Day Perf: -8.01 %
Volume (M): 420 52 Wk High: $ 11.11
Volume (M$): $ 3,476 52 Wk Avg: $4.03
Open: $8.77 52 Wk Low: $1.35



 Market Capitalization (Millions $) 351
 Shares Outstanding (Millions) 42
 Employees -
 Revenues (TTM) (Millions $) 1
 Net Income (TTM) (Millions $) -95
 Cash Flow (TTM) (Millions $) 1
 Capital Exp. (TTM) (Millions $) 1

Shattuck Labs Inc
Shattuck Labs Inc is a biotechnology company that is focused on developing next-generation therapies for cancer treatment. The company was founded in 2016 and is headquartered in Austin, Texas. Shattuck Labs has a broad range of expertise in cancer biology, immunotherapy and drug development.

The company's lead product candidate is called SL-172154, which is an immunotherapy that targets the CD47 trimerization domain. This drug facilitates the phagocytosis of cancer cells by immune cells, which helps to promote an anti-tumor immune response. SL-172154 is currently in Phase 1 clinical trials for patients with solid tumors.

Shattuck Labs has also developed a proprietary platform called Agonist Redirected Checkpoint (ARC) that allows for the generation of novel immunotherapies. The ARC platform combines an agonist ligand that activates immune cells with a checkpoint inhibitor that helps to prevent immunosuppression. This technology can also enable targeted drug delivery to cancer cells, reducing the potential for off-target effects.

In addition to their pipeline of drug candidates, Shattuck Labs has established strategic partnerships with companies such as Takeda Pharmaceuticals and Astellas Pharma. Through these partnerships, the company is able to access additional resources and expertise to further develop their immuno-oncology therapies.

Overall, Shattuck Labs Inc is a dynamic company that is positioned for success in the emerging field of cancer immunotherapy. Their innovative platform technology and promising lead product candidate make them a company to watch in the biotech industry.


   Company Address: 500 W. 5th Street Austin 78701 TX
   Company Phone Number: 900-4690   Stock Exchange / Ticker: NASDAQ STTK
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Licensing Agreement

Shattuck Labs Partners with Ono Pharmaceutical to Develop Innovative Bifunctional Fusion Proteins for Autoimmune and Inflammatory Diseases

Published Tue, Feb 13 2024 11:00 AM UTC

In a groundbreaking move, Shattuck Labs, Inc. (Shattuck) has joined forces with Ono Pharmaceutical Co., Ltd. (Ono) to explore the potential of bifunctional fusion proteins as a novel therapeutic approach for patients suffering from autoimmune and inflammatory diseases. This strategic collaboration aims to leverage the expertise of both companies to develop innovative drugs t...

Stock Market Announcement

Shattuck Labs: A Promising Journey towards Breakthroughs and a Stock Market Surge

Published Mon, Jan 8 2024 12:01 PM UTC

Shattuck Labs Poised for Success: Key Milestones and Soaring Stock Prices
Shattuck Labs, a leading biotechnology company specializing in the development of bi-functional fusion proteins, recently released a corporate update outlining upcoming key milestones for 2024. Alongside this update, the company's stock price has experienced a remarkable rise of 503.28% over the pa...

Clinical Study

Impressive Phase 1 Results Propel Shattuck Labs Ahead Despite Slight Revenue Lag

Published Wed, Dec 13 2023 11:00 AM UTC


Shattuck Labs, Inc. has recently transfixed the medical community after revealing striking initial topline indications from its ongoing Phase 1 A/B Dose Expansion Clinical Trial. The trial, centered on its product SL-172154 combined with Azacitidine, targeted patients suffering from high-risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leuke...

Shattuck Labs Inc

Shattuck Labs Inc Struggles to Turn Profit Despite Massive Revenue Upsurge in Q3, 2023

Shattuck Labs Inc, a clinical-stage biotechnology company, recently announced its third-quarter 2023 financial results and provided a general business overview. The company reported a significant revenue increase of 223.585% year on year to $0.69 million during the third quarter of the 2023 earnings season. However, they also witnessed an increased deficit per share at $-0.65.
This performance by Shattuck Labs Inc came as a surprise to many as the company displayed top-line gains while the rest of the Major Pharmaceutical Preparations sector experienced a 5.64% decline in revenue from the previous quarter. Furthermore, the deficit surged from $-0.50 per share, and revenue doubled by 243% compared to $0.20 million.

Shattuck Labs Inc

Shattuck Labs Inc. Beats the Odds, Achieving 300% Revenue Growth Amidst Industry Challenges



In the midst of a challenging time for the major pharmaceutical preparations industry, Shattuck Labs Inc. has emerged as a shining example of success. With a remarkable revenue increase of 300% year on year, reaching $0.20 million from April to June 2023, the company has defied the odds while many of its competitors struggle with diminishing orders and retracting revenue. Let's delve into the interesting facts surrounding Shattuck Labs Inc.'s recent financial performance and what it means for the stock market.
Impressive Revenue Growth:
Despite a net loss of $0.50 million, the robust revenue elevation of Shattuck Labs Inc. is quite noteworthy. From the previous financial reporting period, the company has reported a doubling of revenue by an astonishing 250.877%, from $0.06 million. Such growth is indicative of the company's ability to capitalize on market opportunities and adapt to the changing landscape. This is particularly important in an industry where uncertainty and market fluctuations are common.






 

Shattuck Labs Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com